Davita Inc vs Wayfair Inc — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while Wayfair Inc trades at $105.86 (market cap $14.40B). The key difference: Wayfair Inc is the larger of the two by market cap, and Wayfair Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Wayfair Inc for 8 Days on average.
| DVA | W | |
|---|---|---|
Market Cap | $11.29B | $14.40B |
Volume | 582,204 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $119.05 |
52-Week Low | $103.87 | $57.40 |
Typical Hold Time | 114 Days | 8 Days |
Enterprise Value | $24.01B | $16.73B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
Wayfair (W) trades at $105.89, up 1.36% with bullish technical signals from moving averages. The company shows revenue growth to $12.9B in 2026 but maintains negative net margins around -2.5%. Recent Q2 2026 earnings beat expectations at $0.95 EPS versus $0.904, while Q3 2026 results are pending. Analyst sentiment is positive with 54% buy ratings and a $114.13 consensus target. The stock faces headwinds from high debt-to-asset ratio of 95.11% and persistent unprofitability despite top-line expansion.
Wayfair presents a mixed outlook with strong revenue growth and technical momentum offset by profitability challenges. The primary opportunity lies in continued market share gains and operational efficiency improvements. Key risks include competitive pressures in e-commerce, high leverage, and macroeconomic sensitivity. Investors should weigh the bullish analyst consensus against fundamental weaknesses in margin performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →